Effectiveness and equity of continuous subcutaneous insulin infusions in pediatric type 1 diabetes: a systematic review and meta-analysis of the literature

Continuous subcutaneous insulin infusions (CSII) are gaining ground over multiple-daily injections (MDI) as a standard therapy for pediatric type 1 diabetes [1]. A number of clinical trials have highlighted that the CSII improve glycemic outcomes, promote patient-centered decisions, and reduce the burden of diabetes care in children and adolescents with type 1 diabetes [2 –9]. However, most of the trials in this field lacked data on clinical effectiveness, the extent to which clinical efficacy of CSII translates into better glycemic outcomes in a real-world setting [10,11].

Source: Diabetes Research and Clinical Practice - December 23, 2020 Category: Endocrinology Authors: Tiago Jeronimo Dos Santos, Juan de Mata Donado Campos, Jes ús Argente, Fernando Rodríguez-Artalejo Tags: Review Source Type: research